18,847 Shares in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Bought by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,847 shares of the company’s stock, valued at approximately $32,000.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC increased its stake in shares of Acumen Pharmaceuticals by 44.2% in the fourth quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock valued at $44,000 after buying an additional 7,859 shares during the period. Barclays PLC boosted its holdings in Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock valued at $154,000 after acquiring an additional 40,551 shares during the last quarter. JPMorgan Chase & Co. increased its position in Acumen Pharmaceuticals by 252.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 63,066 shares of the company’s stock valued at $156,000 after purchasing an additional 45,189 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Acumen Pharmaceuticals by 16.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 126,747 shares of the company’s stock worth $218,000 after purchasing an additional 18,004 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Acumen Pharmaceuticals by 18.3% in the 3rd quarter. State Street Corp now owns 516,406 shares of the company’s stock worth $1,281,000 after purchasing an additional 79,841 shares during the period. 71.01% of the stock is owned by institutional investors.

Insider Transactions at Acumen Pharmaceuticals

In other news, CFO Matt Zuga sold 28,902 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the transaction, the chief financial officer now directly owns 231,744 shares of the company’s stock, valued at $398,599.68. This represents a 11.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the sale, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. The trade was a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock valued at $233,124 in the last 90 days. 7.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABOS has been the topic of a number of analyst reports. UBS Group reduced their price objective on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright decreased their price target on Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating for the company in a report on Friday.

Acumen Pharmaceuticals Price Performance

Acumen Pharmaceuticals stock opened at $1.19 on Friday. The stock has a market capitalization of $71.50 million, a price-to-earnings ratio of -0.86 and a beta of 0.02. Acumen Pharmaceuticals, Inc. has a 52-week low of $1.10 and a 52-week high of $4.06. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. The stock’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.99.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its earnings results on Thursday, March 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.15). On average, equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Acumen Pharmaceuticals Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.